NNC0109-0012

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

InflammationRheumatoid Arthritis

Phase 2

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

TerminatedNCT01636817

Novo Nordisk A/SInflammation, Rheumatoid Arthritis

Start: 2012-08-31End: 2014-11-30Updated: 2018-09-05

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

TerminatedNCT01636843

Novo Nordisk A/SInflammation, Rheumatoid Arthritis

Start: 2012-10-30End: 2014-11-10Updated: 2018-09-05

A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

WithdrawnNCT02097264

Novo Nordisk A/SInflammation, Rheumatoid Arthritis

Start: 2014-09-30End: 2015-09-30Updated: 2014-08-15